Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 31, 2025 07:01 ET | Source: Pasithea

Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients

Pasithea completes enrollment and dosing of first NF1 trial cohort; initial safety and efficacy data expected by Q1 2026.